NO20011351L - Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav - Google Patents

Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav

Info

Publication number: NO20011351L
Authority: NO; Norway
Prior art keywords: inhibitor; combination; treating diabetes; diabetes; glyburide
Prior art date: 1998-09-17

Application number

NO20011351A

Other languages

English (en)

Norwegian (no)

Other versions

NO20011351D0 (no

Inventor

Jeffrey A Robl

Rex A Parker

Scott A Biller

Haris Jamil

Bruce L Jacobson

Krishna Kodukula

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

2001-03-16

Publication date

2001-05-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20011351(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-03-16 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2001-03-16 Publication of NO20011351D0 publication Critical patent/NO20011351D0/no

2001-05-11 Publication of NO20011351L publication Critical patent/NO20011351L/no

Links

239000003112 inhibitor Substances 0.000 title abstract 3
206010012601 diabetes mellitus Diseases 0.000 title abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
229940125708 antidiabetic agent Drugs 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960004580 glibenclamide Drugs 0.000 abstract 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
229960003105 metformin Drugs 0.000 abstract 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 abstract 1
229960001641 troglitazone Drugs 0.000 abstract 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Steroid Compounds (AREA)

NO20011351A 1998-09-17 2001-03-16 Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav NO20011351L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10067798P	1998-09-17	1998-09-17
PCT/US1999/020946 WO2000015229A1 (en)	1998-09-17	1999-09-13	METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Publications (2)

Publication Number	Publication Date
NO20011351D0 NO20011351D0 (no)	2001-03-16
NO20011351L true NO20011351L (no)	2001-05-11

Family

ID=22280975

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20011351A NO20011351L (no)	1998-09-17	2001-03-16	Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav
NO20011352A NO20011352L (no)	1998-09-17	2001-03-16	Fremgangsmåte for behandling av aterosklerose ved anvendelse av en AP2 inhibitor og kombinasjon derav

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20011352A NO20011352L (no)	1998-09-17	2001-03-16	Fremgangsmåte for behandling av aterosklerose ved anvendelse av en AP2 inhibitor og kombinasjon derav

Country Status (30)

Country	Link
US (1)	US20020035064A1 (id)
EP (2)	EP1121129B1 (id)
JP (2)	JP2002524517A (id)
KR (2)	KR20010075150A (id)
CN (2)	CN1319012A (id)
AT (1)	ATE406898T1 (id)
AU (2)	AU755563B2 (id)
BG (2)	BG105432A (id)
BR (2)	BR9913831A (id)
CA (2)	CA2344300A1 (id)
CO (2)	CO5130026A1 (id)
CZ (2)	CZ2001965A3 (id)
DE (1)	DE69939481D1 (id)
EE (2)	EE200100155A (id)
ES (1)	ES2311306T3 (id)
GE (2)	GEP20033045B (id)
HU (2)	HUP0104240A2 (id)
ID (2)	ID28450A (id)
IL (2)	IL141785A0 (id)
LT (2)	LT4871B (id)
LV (2)	LV12686B (id)
NO (2)	NO20011351L (id)
NZ (2)	NZ510209A (id)
PE (2)	PE20001047A1 (id)
PL (2)	PL346661A1 (id)
SK (1)	SK3202001A3 (id)
TR (2)	TR200100773T2 (id)
UY (2)	UY25713A1 (id)
WO (2)	WO2000015229A1 (id)
ZA (2)	ZA200207430B (id)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2259459T3 (es) *	1997-11-19	2006-10-01	Takeda Pharmaceutical Company Limited	Nuevos inhibidores de apoptosis.
AU2005201289B2 (en) *	1999-02-12	2008-04-17	President And Fellows Of Harvard College	Inhibiting formation of atherosclerotic lesions
JP2002536459A (ja) *	1999-02-12	2002-10-29	プレジデントアンドフェローズオブハーヴァードカレッジ	アテローム性動脈硬化症性病変の形成の阻害
US6548529B1 (en) *	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en)	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
WO2001054694A1 (en)	2000-01-28	2001-08-02	Bristol-Myers Squibb Company	Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
EP1343763A1 (en)	2000-11-20	2003-09-17	Bristol-Myers Squibb Company	Pyrodone derivatives as ap2 inhibitors
AU2002254940A1 (en) *	2001-03-12	2002-09-24	Novartis Pharma Gmbh	Combination of nateglinide or repaglinide with at least one further antidiabetic compound
WO2003006023A1 (en)	2001-07-13	2003-01-23	Bristol-Myers Squibb Company	Pyrazinone inhibitors of fatty acid binding protein and method
WO2003007888A2 (en) *	2001-07-20	2003-01-30	Adipogenix, Inc.	Fat accumulation-modulating compounds
EP1443919A4 (en)	2001-11-16	2006-03-22	Bristol Myers Squibb Co	DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
US7572922B2 (en)	2003-01-27	2009-08-11	Merck & Co., Inc.	Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004084890A1 (en) *	2003-03-26	2004-10-07	Crc For Asthma Limited	Therapeutic and prophylactic compositions and uses therefor
WO2004096977A2 (en) *	2003-04-30	2004-11-11	Pfizer Products Inc.	Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
PT1725234E (pt)	2004-03-05	2013-03-04	Univ Pennsylvania	Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia
SI1756064T1 (sl)	2004-06-04	2008-12-31	Merck & Co Inc	Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
WO2006028970A1 (en)	2004-09-02	2006-03-16	Cengent Therapeutics, Inc.	Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
NZ560712A (en)	2005-02-17	2010-12-24	Synta Pharmaceuticals Corp	(3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
JP2009502923A (ja)	2005-07-26	2009-01-29	メルクエンドカムパニーインコーポレーテッド	置換ピラゾールを合成するための方法
EP1951220A2 (en) *	2005-10-18	2008-08-06	Aegerion Pharmaceuticals	Compositions for lowering serum cholesterol and/or triglycerides
WO2007143164A1 (en) *	2006-06-02	2007-12-13	San Diego State University Research Foundation	Compositions and methods for ameliorating hyperlipidemia
JP2010513534A (ja) *	2006-12-21	2010-04-30	エージェリオンファーマシューティカルズ，インコーポレイテッド	Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
WO2010056631A1 (en) *	2008-11-12	2010-05-20	Schering Corporation	Inhibitors of fatty acid binding protein (fabp)
PT2403605E (pt) *	2009-03-05	2015-08-05	Harvard College	Composições contendo um anticorpo específico de ap2 ou um seu fragmento, para serem utilizadas no tratamento de diabetes, intolerância à glicose ou resistência à insulina induzida por obesidade
JP6514282B2 (ja) *	2014-03-24	2019-05-15	花王株式会社	Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6223376B2 (ja)	2014-03-24	2017-11-01	花王株式会社	Ｇｉｐ上昇抑制剤の評価又は選択方法
KR20170138570A (ko)	2015-04-30	2017-12-15	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
CA3026521A1 (en) *	2016-06-27	2018-01-04	President And Fellows Of Harvard College	Compounds useful to treat metabolic disorders
AU2018279950A1 (en)	2017-06-09	2020-01-30	President And Fellows Of Harvard College	Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
AU2021297465A1 (en)	2020-06-27	2023-03-02	Crescenta Biosciences	Novel cell metabolism modulating compounds and uses thereof
BR112023000808A2 (pt)	2020-07-29	2023-02-07	Amryt Pharmaceuticals Inc	Lomitapida para uso em métodos para tratar hiperlipidemia e hipercolesterolemia em pacientes pediátricos
US12138243B2 (en)	2021-12-31	2024-11-12	Crescenta Biosciences	Antiviral use of FABP4 modulating compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2129012A1 (de)	1971-06-11	1973-01-04	Merck Patent Gmbh	Azol-derivate
FR2156486A1 (en)	1971-10-22	1973-06-01	Roussel Uclaf	Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (id)	1974-06-07	1981-03-18
GB1507032A (en)	1974-08-06	1978-04-12	Serono Lab	2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no)	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
CA1327360C (en)	1983-11-14	1994-03-01	William F. Hoffman	Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
DK277488A (da)	1987-05-22	1988-11-23	Squibb & Sons Inc	Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
PT95690A (pt) *	1989-10-27	1991-09-13	American Home Prod	Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5218124A (en) *	1989-10-27	1993-06-08	American Home Products Corporation	Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
US5262540A (en) *	1989-12-20	1993-11-16	Bristol-Myers Squibb Company	[2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr)	1990-06-14	1994-05-06	Bellon Laboratoires	Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) *	1990-09-11	1990-10-24	Smith Kline French Lab	Compounds
US5348969A (en) *	1992-04-03	1994-09-20	Bristol-Myers Squibb Company	Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) *	1992-04-03	1993-02-16	Bristol-Myers Squibb Company	Oxazole carboxylic acid derivatives
US5254576A (en) *	1992-04-03	1993-10-19	Bristol-Myers Squibb Company	Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5594016A (en)	1992-12-28	1997-01-14	Mitsubishi Chemical Corporation	Naphthalene derivatives
US5346701A (en)	1993-02-22	1994-09-13	Theratech, Inc.	Transmucosal delivery of macromolecular drugs
US5362879A (en) *	1993-04-15	1994-11-08	Bristol-Myers Squibb Company	4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de)	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
DK0736018T3 (da) *	1993-12-20	2000-09-18	Fujisawa Pharmaceutical Co	4,5-Diaryloxazolderivater
US5599770A (en)	1994-07-15	1997-02-04	Kureha Kagaku Kogyo Kabushiki Kaisha	Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
WO1996004261A1 (en)	1994-07-29	1996-02-15	Smithkline Beecham Plc	Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk)	1995-05-08	2003-06-16	Фармація Енд Апджон Компані	<font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997012613A1 (en)	1995-10-05	1997-04-10	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en)	1996-01-05	1996-03-06	Foster Wheeler Petrol Dev Ltd	Spacing bouy for flexible risers
AUPO134596A0 (en)	1996-08-01	1996-08-22	Jal Pastoral Co. Pty Ltd	Demountable article carrier for motor vehicles
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

1999
- 1999-09-13 EE EEP200100155A patent/EE200100155A/xx unknown
- 1999-09-13 NZ NZ510209A patent/NZ510209A/en unknown
- 1999-09-13 IL IL14178599A patent/IL141785A0/xx unknown
- 1999-09-13 AT AT99951438T patent/ATE406898T1/de not_active IP Right Cessation
- 1999-09-13 KR KR1020017003411A patent/KR20010075150A/ko not_active Withdrawn
- 1999-09-13 DE DE69939481T patent/DE69939481D1/de not_active Revoked
- 1999-09-13 HU HU0104240A patent/HUP0104240A2/hu unknown
- 1999-09-13 GE GEAP19995860A patent/GEP20033045B/en unknown
- 1999-09-13 CA CA002344300A patent/CA2344300A1/en not_active Abandoned
- 1999-09-13 ID IDW20010624A patent/ID28450A/id unknown
- 1999-09-13 BR BR9913831-0A patent/BR9913831A/pt not_active IP Right Cessation
- 1999-09-13 WO PCT/US1999/020946 patent/WO2000015229A1/en not_active Ceased
- 1999-09-13 PL PL99346661A patent/PL346661A1/xx unknown
- 1999-09-13 HU HU0104108A patent/HUP0104108A2/hu unknown
- 1999-09-13 NZ NZ510207A patent/NZ510207A/en unknown
- 1999-09-13 CZ CZ2001965A patent/CZ2001965A3/cs unknown
- 1999-09-13 JP JP2000569813A patent/JP2002524517A/ja active Pending
- 1999-09-13 KR KR1020017003408A patent/KR20010079842A/ko not_active Withdrawn
- 1999-09-13 IL IL14178699A patent/IL141786A0/xx unknown
- 1999-09-13 ID IDW20010626A patent/ID27833A/id unknown
- 1999-09-13 WO PCT/US1999/021069 patent/WO2000015230A1/en not_active Ceased
- 1999-09-13 JP JP2000569814A patent/JP2002524518A/ja active Pending
- 1999-09-13 TR TR2001/00773T patent/TR200100773T2/xx unknown
- 1999-09-13 SK SK320-2001A patent/SK3202001A3/sk unknown
- 1999-09-13 BR BR9913833-6A patent/BR9913833A/pt not_active IP Right Cessation
- 1999-09-13 CA CA002344309A patent/CA2344309A1/en not_active Abandoned
- 1999-09-13 CN CN99811096A patent/CN1319012A/zh active Pending
- 1999-09-13 PL PL99346660A patent/PL346660A1/xx not_active Application Discontinuation
- 1999-09-13 AU AU61437/99A patent/AU755563B2/en not_active Ceased
- 1999-09-13 CZ CZ2001964A patent/CZ2001964A3/cs unknown
- 1999-09-13 AU AU63877/99A patent/AU754488B2/en not_active Ceased
- 1999-09-13 EE EEP200100154A patent/EE04356B1/xx not_active IP Right Cessation
- 1999-09-13 TR TR2001/00774T patent/TR200100774T2/xx unknown
- 1999-09-13 EP EP99951438A patent/EP1121129B1/en not_active Revoked
- 1999-09-13 EP EP99948210A patent/EP1113801A4/en not_active Withdrawn
- 1999-09-13 GE GEAP19995861A patent/GEP20033044B/en unknown
- 1999-09-13 CN CN99811000A patent/CN1317970A/zh active Pending
- 1999-09-13 ES ES99951438T patent/ES2311306T3/es not_active Expired - Lifetime
- 1999-09-15 CO CO99058376A patent/CO5130026A1/es unknown
- 1999-09-15 CO CO99058374A patent/CO5130025A1/es unknown
- 1999-09-16 UY UY25713A patent/UY25713A1/es unknown
- 1999-09-16 UY UY25714A patent/UY25714A1/es unknown
- 1999-09-17 PE PE1999000944A patent/PE20001047A1/es not_active Application Discontinuation
- 1999-09-17 PE PE1999000943A patent/PE20001056A1/es not_active Application Discontinuation
2001
- 2001-03-16 LT LT2001022A patent/LT4871B/lt not_active IP Right Cessation
- 2001-03-16 NO NO20011351A patent/NO20011351L/no unknown
- 2001-03-16 NO NO20011352A patent/NO20011352L/no not_active Application Discontinuation
- 2001-03-16 LT LT2001023A patent/LT4870B/lt not_active IP Right Cessation
- 2001-04-10 BG BG105432A patent/BG105432A/xx unknown
- 2001-04-10 BG BG105431A patent/BG105431A/xx unknown
- 2001-04-12 LV LV010057A patent/LV12686B/xx unknown
- 2001-04-12 LV LV010058A patent/LV12687B/xx unknown
- 2001-07-13 US US09/905,235 patent/US20020035064A1/en not_active Abandoned
2002
- 2002-09-16 ZA ZA200207430A patent/ZA200207430B/en unknown
- 2002-09-16 ZA ZA200207433A patent/ZA200207433B/en unknown

Also Published As

Publication number	Publication date
EP1121129B1 (en)	2008-09-03
CZ2001964A3 (cs)	2002-01-16
TR200100774T2 (tr)	2001-12-21
EP1121129A4 (en)	2002-10-16
ZA200207430B (en)	2003-09-16
EE200100154A (et)	2002-12-16
NO20011352D0 (no)	2001-03-16
PL346661A1 (en)	2002-02-25
ATE406898T1 (de)	2008-09-15
EE04356B1 (et)	2004-10-15
AU754488B2 (en)	2002-11-14
SK3202001A3 (en)	2002-04-04
US20020035064A1 (en)	2002-03-21
PL346660A1 (en)	2002-02-25
JP2002524518A (ja)	2002-08-06
LV12687A (en)	2001-07-20
JP2002524517A (ja)	2002-08-06
PE20001056A1 (es)	2000-12-24
PE20001047A1 (es)	2000-12-24
AU6143799A (en)	2000-04-03
BR9913833A (pt)	2001-05-29
NZ510207A (en)	2003-08-29
WO2000015230A1 (en)	2000-03-23
AU755563B2 (en)	2002-12-12
IL141785A0 (en)	2002-03-10
GEP20033044B (en)	2003-08-25
TR200100773T2 (tr)	2001-07-23
KR20010079842A (ko)	2001-08-22
KR20010075150A (ko)	2001-08-09
HUP0104108A2 (hu)	2002-03-28
ES2311306T3 (es)	2009-02-01
CA2344300A1 (en)	2000-03-23
CA2344309A1 (en)	2000-03-23
CO5130025A1 (es)	2002-02-27
EP1113801A4 (en)	2002-10-02
EP1113801A1 (en)	2001-07-11
EE200100155A (et)	2002-08-15
HUP0104240A2 (hu)	2002-03-28
UY25713A1 (es)	2001-08-27
WO2000015229A1 (en)	2000-03-23
CO5130026A1 (es)	2002-02-27
ZA200207433B (en)	2003-10-27
LV12687B (lv)	2001-10-20
EP1121129A1 (en)	2001-08-08
LT4871B (lt)	2001-12-27
LV12686B (lv)	2001-10-20
IL141786A0 (en)	2002-03-10
BG105431A (en)	2001-12-29
BR9913831A (pt)	2001-05-29
LV12686A (en)	2001-07-20
NO20011351D0 (no)	2001-03-16
DE69939481D1 (de)	2008-10-16
UY25714A1 (es)	2001-08-27
CZ2001965A3 (cs)	2002-02-13
NO20011352L (no)	2001-05-11
ID27833A (id)	2001-04-26
ID28450A (id)	2001-05-24
GEP20033045B (en)	2003-08-25
LT4870B (lt)	2001-12-27
CN1319012A (zh)	2001-10-24
BG105432A (en)	2001-12-29
CN1317970A (zh)	2001-10-17
LT2001023A (en)	2001-08-27
LT2001022A (en)	2001-08-27
AU6387799A (en)	2000-04-03
NZ510209A (en)	2003-07-25

Publication	Publication Date	Title
BG105431A (en)	2001-12-29	METHOD FOR TREATING DIABETES EMPLOYING AN Ap2 INHIBITOR AND COMBINATION
LT2001092A (en)	2002-02-25	HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND USE THEREOF
BR9809968A (pt)	2000-08-01	Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional
DK1011673T3 (da)	2001-07-09	Hidtil ukendt metode til behandling af nidom
BR9714505A (pt)	2000-03-21	para o diabetes.
NO20044534L (no)	2004-12-22	Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
UY34691A (es)	2014-10-31	Inhibidores a base de pirrolidina fusionada con ciclopropilo de dipeptidil peptidasa iv y método
ATE238802T1 (de)	2003-05-15	Zusammensetzung von glibenclamid und metformine zur behandlung von diabetes mellitis typ ii
DK1128834T3 (da)	2005-07-04	Kombinationer til diabetes, som indeholder glyburid, troglitazon (og et biguanid)
ATE246681T1 (de)	2003-08-15	Sulfonamide
PT97431A (pt)	1991-12-31	Processo para a preparacao de derivados de benzo-isotiazole
DK0749421T3 (da)	2000-03-20	Sulfonamidderivater som aspartylproteaseinhibitorer
EP0400557A3 (en)	1991-11-06	Developing apparatus and process cartridge with same
BR9501764A (pt)	1995-11-21	Pirazol de piridila substituído processo para sua preparação,composição pesticida método para o combate de artrópodos uso composição inseticida processo para a preparação de composições composto composição artropodicida e processo para a preparação da composição
PT89502A (pt)	1989-10-04	Processo para a preparacao de derivados de 2-(2-hidroxi-3-fenoxi-metilo e de composicoes farmaceuticas que os contem
NO951790D0 (no)	1995-05-08	Nytt arylpropionsyrederivat, fremgangsmåte ved dets fremstilling og dets anvendelse som et analgetisk middel
NO306930B1 (no)	2000-01-17	Anvendelse av 2-amino-6-n-propylamino-4,5,6,7- tetrahydrobenzotiazol (Pramipexol) som et antidepressivt middel
EE9700094A (et)	1997-10-15	Aminoguanidiinkarboksülaadid insuliinisõltumatu suhkurtõve raviks
IL120443A (en)	2000-07-16	Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
ES2187534T3 (es)	2003-06-16	Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida.
NO996270L (no)	1999-12-17	Behandling av diabetes med tiazolidindion og <alfa>- glukosidaseinhibitor
AU6454196A (en)	1997-03-05	Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
BR9810292A (pt)	2000-09-19	Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
TR26593A (tr)	1995-03-15	HIDROFIL DURUM GETIRILMIS TRIGLISERID'LERIN üRETILMESINE MAHSUS USUL.
BR9807785A (pt)	2000-02-22	Processo para a preparação do composto, e, composto